Kymera Investor Day Presentation Deck

● ● ● ● What We Expect in 2022 Completion of Ph1 patient cohort for KT-474 and transition to Sanofi Proof of mechanism in patients for KT-413 and KT-333 oncology Ph1 studies IND filing for KT-253 First tissue restricted E3 ligase enabled program in development Continued growth of team and capabilities Expanded recognition as a leader in TPD with a disruptive innovation engine across the biotech sector Multiple scientific contributions in medical meetings and in peer reviewed publications Continued investment in providing our employees, collaborator and partners the best experience KYMERA ©2021 KYMERA THERAPEUTICS, INC. KYMERA R&D DAY - December 16th, 2021 PAGE 101

View entire presentation